Expression of Concern: Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial (Clin Endocrinol (Oxf), 84, 6, (851-857), 10.1111/cen.13003);Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial

Clinical Endocrinology

Volumn 84, Issue 6, 2016, Pages 851-857

  Samimi, Mansooreh ^a   Jamilian, Mehri ^b   Ebrahimi, Faraneh Afshar ^a   Rahimi, Maryam ^c   Tajbakhsh, Banafsheh ^d   Asemi, Zatollah ^a  

^a KASHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ARAK UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d YASUJ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRASTERONE SULFATE; TESTOSTERONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; GLUCOSE BLOOD LEVEL; LIPID;

ABSENCE OF SIDE EFFECTS; ADULT; ANOVULATION; ARTICLE; BLOOD SAMPLING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HIP CIRCUMFERENCE; HUMAN; HYPERANDROGENISM; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID HOMEOSTASIS; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; ADOLESCENT; BLOOD; DIETARY SUPPLEMENT; DRUG EFFECTS; MORPHOMETRY; ORAL DRUG ADMINISTRATION; OVERWEIGHT; PATHOPHYSIOLOGY; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BLOOD GLUCOSE; BODY WEIGHTS AND MEASURES; CARNITINE; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; LIPIDS; OVERWEIGHT; POLYCYSTIC OVARY SYNDROME; WEIGHT LOSS; YOUNG ADULT;

EID: 84958212874     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.14891     Document Type: Erratum

References (34)

1. Pau, C.T., Keefe, C., Duran, J., et al,. (2014) Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study. Journal of Clinical Endocrinology and Metabolism, 99, 1870-1878.
2. Crosignani, P.G., Colombo, M., Vegetti, W., et al,. (2003) Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Human Reproduction, 18, 1928-1932.
3. Thomson, R.L., Brinkworth, G.D., Noakes, M., et al,. (2012) The effect of diet and exercise on markers of endothelial function in overweight and obese women with polycystic ovary syndrome. Human Reproduction, 27, 2169-2176.
4. Dunaif, A., Segal, K.R., Futterweit, W., et al,. (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes, 38, 1165-1174.
5. Weerakiet, S., Srisombut, C., Bunnag, P., et al,. (2001) Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome. International Journal of Gynaecology and Obstetrics, 75, 177-184.
6. Welt, C.K., Arason, G., Gudmundsson, J.A., et al,. (2006) Defining constant versus variable phenotypic features of women with polycystic ovary syndrome using different ethnic groups and populations. Journal of Clinical Endocrinology and Metabolism, 91, 4361-4368.
7. Power, R.A., Hulver, M.W., Zhang, J.Y., et al,. (2007) Carnitine revisited: potential use as adjunctive treatment in diabetes. Diabetologia, 50, 824-832.
8. Fenkci, S.M., Fenkci, V., Oztekin, O., et al,. (2008) Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome. Human Reproduction, 23, 1602-1606.
9. Hathcock, J.N., &, Shao, A., (2006) Risk assessment for carnitine. Regulatory Toxicology and Pharmacology, 46, 23-28.
10. Vigerust, N.F., Bohov, P., Bjorndal, B., et al,. (2012) Free carnitine and acylcarnitines in obese patients with polycystic ovary syndrome and effects of pioglitazone treatment. Fertility and Sterility, 98, 1620-1626 e1621.
11. Ismail, A.M., Hamed, A.H., Saso, S., et al,. (2014) Adding L-carnitine to clomiphene resistant PCOS women improves the quality of ovulation and the pregnancy rate. A randomized clinical trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 180, 148-152.
12. Zhang, J.J., Wu, Z.B., Cai, Y.J., et al,. (2014) L-carnitine ameliorated fasting-induced fatigue, hunger, and metabolic abnormalities in patients with metabolic syndrome: a randomized controlled study. Nutrition Journal, 13, 110.
13. Ringseis, R., Keller, J., &, Eder, K., (2012) Role of carnitine in the regulation of glucose homeostasis and insulin sensitivity: evidence from in vivo and in vitro studies with carnitine supplementation and carnitine deficiency. European Journal of Nutrition, 51, 1-18.
14. Wall, B.T., Stephens, F.B., Constantin-Teodosiu, D., et al,. (2011) Chronic oral ingestion of L-carnitine and carbohydrate increases muscle carnitine content and alters muscle fuel metabolism during exercise in humans. Journal of Physiology, 589, 963-973.
15. Elmslie, J.L., Porter, R.J., Joyce, P.R., et al,. (2006) Carnitine does not improve weight loss outcomes in valproate-treated bipolar patients consuming an energy-restricted, low-fat diet. Bipolar Disorders, 8, 503-507.
16. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility, 81, 19-25.
17. Jamilian, M., Razavi, M., Fakhrie Kashan, Z., et al,. (2015) Metabolic response to selenium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf), 82, 885-891.
18. Molfino, A., Cascino, A., Conte, C., et al,. (2010) Caloric restriction and L-carnitine administration improves insulin sensitivity in patients with impaired glucose metabolism. JPEN. Journal of Parenteral and Enteral Nutrition, 34, 295-299.
19. Jamilian, M., Foroozanfard, F., Bahmani, F., et al,. (2015) Effects of zinc supplementation on endocrine outcomes in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Biological Trace Element Research, 170, 271-278.
20. Pisprasert, V., Ingram, K.H., Lopez-Davila, M.F., et al,. (2013) Limitations in the use of indices using glucose and insulin levels to predict insulin sensitivity: impact of race and gender and superiority of the indices derived from oral glucose tolerance test in African Americans. Diabetes Care, 36, 845-853.
21. Bargiota, A., &, Diamanti-Kandarakis, E., (2012) The effects of old, new and emerging medicines on metabolic aberrations in PCOS. Ther Adv Endocrinol Metab, 3, 27-47.
22. Center, S.A., Harte, J., Watrous, D., et al,. (2000) The clinical and metabolic effects of rapid weight loss in obese pet cats and the influence of supplemental oral L-carnitine. Journal of Veterinary Internal Medicine, 14, 598-608.
23. Villani, R.G., Gannon, J., Self, M., et al,. (2000) L-Carnitine supplementation combined with aerobic training does not promote weight loss in moderately obese women. International Journal of Sport Nutrition and Exercise Metabolism, 10, 199-207.
24. Muller, D.M., Seim, H., Kiess, W., et al,. (2002) Effects of oral L-carnitine supplementation on in vivo long-chain fatty acid oxidation in healthy adults. Metabolism, 51, 1389-1391.
25. Center, S.A., Warner, K.L., Randolph, J.F., et al,. (2012) Influence of dietary supplementation with (L)-carnitine on metabolic rate, fatty acid oxidation, body condition, and weight loss in overweight cats. American Journal of Veterinary Research, 73, 1002-1015.
26. Capaldo, B., Napoli, R., Di Bonito, P., et al,. (1991) Carnitine improves peripheral glucose disposal in non-insulin-dependent diabetic patients. Diabetes Research and Clinical Practice, 14, 191-195.
27. Ruggenenti, P., Cattaneo, D., Loriga, G., et al,. (2009) Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy. Hypertension, 54, 567-574.
28. Derosa, G., Cicero, A.F., Gaddi, A., et al,. (2003) The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clinical Therapeutics, 25, 1429-1439.
29. Stephens, F.B., Constantin-Teodosiu, D., &, Greenhaff, P.L., (2007) New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. Journal of Physiology, 581, 431-444.
30. Bremer, J., (1990) The role of carnitine in intracellular metabolism. Journal of Clinical Chemistry and Clinical Biochemistry, 28, 297-301.
31. Golper, T.A., Wolfson, M., Ahmad, S., et al,. (1990) Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects. Kidney International, 38, 904-911.
32. Malaguarnera, M., Vacante, M., Avitabile, T., et al,. (2009) L-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes. American Journal of Clinical Nutrition, 89, 71-76.
33. Emami Naini, A., Moradi, M., Mortazavi, M., et al,. (2012) Effects of Oral L-Carnitine Supplementation on Lipid Profile, Anemia, and Quality of Life in Chronic Renal Disease Patients under Hemodialysis: A Randomized, Double-Blinded, Placebo-Controlled Trial. J Nutr Metab, 2012, 510483.
34. Guarnieri, G.F., Ranieri, F., Toigo, G., et al,. (1980) Lipid-lowering effect of carnitine in chronically uremic patients treated with maintenance hemodialysis. American Journal of Clinical Nutrition, 33, 1489-1492.